Mesenchymal stem cells protect against the tissue fibrosis of ketamine-induced cystitis in rat bladder

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Kim, Aram ^a   Yu, Hwan Yeul ^a   Heo, Jinbeom ^a   Song, Miho ^a   Shin, Jung Hyun ^a   Lim, Jisun ^a   Yoon, Soo Jung ^a   Kim, Yonghwan ^a   Lee, Seungun ^a   Kim, Seong Who ^a   Oh, Wonil ^b   Choi, Soo Jin ^b   Shin, Dong Myung ^a   Choo, Myung Soo ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b MEDIPOST Co Ltd   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; KETAMINE; PROTECTIVE AGENT;

ANIMAL; BLADDER; CELL CULTURE; CHEMICALLY INDUCED; CYSTITIS; CYTOLOGY; DISEASE MODEL; FIBROSIS; HUMAN; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; NEWBORN; PATHOPHYSIOLOGY; RAT; SPRAGUE DAWLEY RAT;

ANALGESICS; ANIMALS; CELLS, CULTURED; CYSTITIS; DISEASE MODELS, ANIMAL; FIBROSIS; HUMANS; INFANT, NEWBORN; KETAMINE; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; PROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; URINARY BLADDER;

EID: 84982694878     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep30881     Document Type: Article

References (57)

1. Chu, P. S. et al. 'Street ketamine'-associated bladder dysfunction: a report of ten cases. Hong Kong Med. J. 13, 311-313 (2007).
2. Phatak, S., Foster, H. E. Jr. The management of interstitial cystitis: an update. Nat. Clin. Pract. Urol. 3, 45-53 (2006).
3. van de Merwe, J. P. et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur. Urol. 53, 60-67 (2008).
4. Persson, J. Wherefore ketamine? Curr. Opin. Anaesthesiol. 23, 455-460 (2010).
5. Lee, J.-D., Lee, M.-H. Activation of Extrinsic Apoptotic Pathway From Bladder Biopsy in Patients With Interstitial Cystitis/Painful Bladder Syndrome. Urology 82, 1451.e1457-1451.e1411 (2013).
6. Song, M. et al. Mesenchymal Stem Cell Therapy Alleviates Interstitial Cystitis by Activating Wnt Signaling Pathway. Stem Cells Dev 24, 1648-1657 (2015).
7. Chu, P. S. et al. The destruction of the lower urinary tract by ketamine abuse: a new syndrome? BJU Int. 102, 1616-1622 (2008).
8. Ratliff, T. L., Klutke, C. G., McDougall, E. M. The etiology of interstitial cystitis. Urol. Clin. North Am. 21, 21-30 (1994).
9. Misra, S., Chetwood, A., Coker, C., Thomas, P. Ketamine cystitis: practical considerations in management. Scand J Urol 48, 482-488 (2014).
10. Giannantoni, A. et al. Contemporary management of the painful bladder: a systematic review. Eur. Urol. 61, 29-53 (2012).
11. Kim, A., Shin, D.-M., Choo, M.-S. Stem Cell Therapy for Interstitial Cystitis/Bladder Pain Syndrome. Curr Urol Rep 17, 1-9 (2015).
12. Damien, P., Allan, D. S. Regenerative Therapy and Immune Modulation Using Umbilical Cord Blood-Derived Cells. Biol. Blood Marrow Transplant. 21, 1545-1554 (2015).
13. Jaing, T.-H. Umbilical Cord Blood: A Trustworthy Source of Multipotent Stem Cells for Regenerative Medicine. Cell Transplantation 23, 493-496 (2014).
14. Bianco, P. et al. The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. Nat Med 19, 35-42 (2013).
15. Murray, I. et al. Natural history of mesenchymal stem cells, from vessel walls to culture vessels. Cell. Mol. Life Sci. 71, 1353-1374 (2014).
16. Lim, J.-Y. et al. Enhanced immunoregulation of mesenchymal stem cells by IL-10-producing type 1 regulatory T cells in collageninduced arthritis. Sci. Rep. 6, 26851 (2016).
17. Gholizadeh-Ghalehaziz, S., Farahzadi, R., Fathi, E., Pashaiasl, M. A Mini Overview of Isolation, Characterization and Application of Amniotic Fluid Stem Cells. Int J Stem Cells 8, 115-120 (2015).
18. Fan, Y.-P. et al. The Therapeutic Potential of Human Umbilical Mesenchymal Stem Cells From Wharton's Jelly in the Treatment of Rat Peritoneal Dialysis-Induced Fibrosis. Stem Cells Transl Med 5, 235-247 (2016).
19. Cutler, A. J., Limbani, V., Girdlestone, J., Navarrete, C. V. Umbilical Cord-Derived Mesenchymal Stromal Cells Modulate Monocyte Function to Suppress T Cell Proliferation. J. Immunol. 185, 6617-6623 (2010).
20. Liu, Y. et al. Contribution and Mobilization of Mesenchymal Stem Cells in a mouse model of carbon tetrachloride-induced liver fibrosis. Scientific Reports 5, 17762 (2015).
21. Zhang, Y. et al. Potent Paracrine Effects of human induced Pluripotent Stem Cell-derived Mesenchymal Stem Cells Attenuate Doxorubicin-induced Cardiomyopathy. Sci. Rep. 5, 11235 (2015).
22. Maria, A. T. J. et al. Anti-fibrotic, anti-oxidant and immunomodulatory effects of mesenchymal stem cells in HOCl-induced systemic sclerosis. Arthritis Rheumatol 68, 1013-1025 (2016).
23. Usunier, B., Benderitter, M., Tamarat, R., Chapel, A. Management of Fibrosis: The Mesenchymal Stromal Cells Breakthrough. Stem Cells Int 2014, 26 (2014).
24. Atoui, R., Chiu, R. C. J. Concise Review: Immunomodulatory Properties of Mesenchymal Stem Cells in Cellular Transplantation: Update, Controversies, and Unknowns. Stem Cells Transl Med 1, 200-205 (2012).
25. Takahashi, T. et al. Multipotent Mesenchymal Stromal Cells Synergize With Costimulation Blockade in the Inhibition of Immune Responses and the Induction of Foxp3 + Regulatory T Cells. Stem Cells Transl Med 3, 1484-1494 (2014).
26. Gu, W. et al. Mesenchymal stem cells alleviate airway inflammation and emphysema in COPD through down-regulation of cyclooxygenase-2 via p38 and ERK MAPK pathways. Sci. Rep. 5, 8733 (2015).
27. Lin, C.-S., Lue, T. In Adipose Stem Cells and Regenerative Medicine, (eds Illouz, Yves-Gerard & Sterodimas, Aris) Ch. 18, 193-207 (Springer, 2011).
28. Song, M. et al. The paracrine effects of mesenchymal stem cells stimulate the regeneration capacity of endogenous stem cells in the repair of a bladder-outlet-obstruction-induced overactive bladder. Stem Cells Dev 23, 654-663 (2014).
29. Wezel, F., Southgate, J., Thomas, D. F. M. Regenerative medicine in urology. BJU Int. 108, 1046-1065 (2011).
30. Song, M. et al. The fibrosis of ketamine, a noncompetitive N-methyl-d-aspartic acid receptor antagonist dose-dependent change in a ketamine-induced cystitis rat model. Drug Chem. Toxicol. 39, 206-212 (2016).
31. Richter, B. et al. YKL-40 and mast cells are associated with detrusor fibrosis in patients diagnosed with bladder pain syndrome/interstitial cystitis according to the 2008 criteria of the European Society for the Study of Interstitial Cystitis. Histopathology 57, 371-383 (2010).
32. Lee, C. L., Jiang, Y. H., Kuo, H. C. Increased apoptosis and suburothelial inflammation in patients with ketamine-related cystitis: a comparison with non-ulcerative interstitial cystitis and controls. BJU Int. 112, 1156-1162 (2013).
33. Onishi, A. et al. Attenuation of methylglyoxal-induced peritoneal fibrosis: immunomodulation by interleukin-10. Lab Invest 95, 1353-1362 (2015).
34. Samarakoon, R., Overstreet, J. M., Higgins, P. J. TGF-? signaling in tissue fibrosis: Redox controls, target genes and therapeutic opportunities. Cell. Signal. 25, 264-268 (2013).
35. Hunninghake, G. W. Antioxidant therapy for idiopathic pulmonary fibrosis. N. Engl. J. Med. 353, 2285-2287 (2005).
36. Demedts, M. et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 353, 2229-2242 (2005).
37. Gu, D. et al. Long-term ketamine abuse induces cystitis in rats by impairing the bladder epithelial barrier. Mol. Biol. Rep. 41, 7313-7322 (2014).
38. Johnson, A., DiPietro, L. A. Apoptosis and angiogenesis: an evolving mechanism for fibrosis. FASEB J. 27, 3893-3901 (2013).
39. Mason, K., Cottrell, A. M., Corrigan, A. G., Gillatt, D. A., Mitchelmore, A. E. Ketamine-associated lower urinary tract destruction: a new radiological challenge. Clin. Radiol. 65, 795-800 (2010).
40. Shahani, R., Streutker, C., Dickson, B., Stewart, R. J. Ketamine-associated ulcerative cystitis: a new clinical entity. Urology 69, 810-812 (2007).
41. Yeung, L. Y., Rudd, J. A., Lam, W. P., Mak, Y. T., Yew, D. T. Mice are prone to kidney pathology after prolonged ketamine addiction. Toxicol. Lett. 191, 275-278 (2009).
42. Shen, C. H. et al. Biological effect of ketamine in urothelial cell lines and global gene expression analysis in the bladders of ketamineinjected mice. Mol Med Rep 11, 887-895 (2015).
43. Gu, D. et al. Effects of long-term ketamine administration on rat bladder protein levels: A proteomic investigation using twodimensional difference gel electrophoresis system. International Journal of Urology 20, 1024-1031 (2013).
44. Li, X., Long, Q., Cheng, X., He, D. Shock Wave Induces Biological Renal Damage by Activating Excessive Inflammatory Responses in Rat Model. Inflammation 37, 1317-1325 (2014).
45. Akhurst, R. J., Padgett, R. W. Matters of context guide future research in TGF? superfamily signaling. Sci Signal 8, 10-10 (2015).
46. Liu, H. T., Jiang, Y. H., Kuo, H. C. Alteration of Urothelial Inflammation, Apoptosis, and Junction Protein in Patients with Various Bladder Conditions and Storage Bladder Symptoms Suggest Common Pathway Involved in Underlying Pathophysiology. Low Urin Tract Symptoms 7, 102-107 (2015).
47. Sant, G. R., Theoharides, T. C. The role of the mast cell in interstitial cystitis. Urol. Clin. North Am. 21, 41-53 (1994).
48. Church, M. K., Lowman, M. A., Rees, P. H., Benyon, R. C. Mast-Cells, Neuropeptides and Inflammation. Agents Actions 27, 9-16 (1989).
49. Galli, S. J. Seminars in Medicine of the Beth-Israel-Hospital, Boston-New Concepts About the Mast-Cell. N. Engl. J. Med. 328, 257-265 (1993).
50. Knaän-Shanzer, S. Concise Review: The Immune Status of Mesenchymal Stem Cells and Its Relevance for Therapeutic Application. Stem Cells 32, 603-608 (2014).
51. Maumus, M., Guerit, D., Toupet, K., Jorgensen, C., Noel, D. Mesenchymal stem cell-based therapies in regenerative medicine: applications in rheumatology. Stem Cell. Res. Ther. 2, 14 (2011).
52. Connick, P. et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol. 11, 150-156 (2012).
53. Wang, D. et al. Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study. Arthritis Res. Ther. 16, R79 (2014).
54. de la Portilla, F. et al. Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn's disease: results from a multicenter phase I/IIa clinical trial. Int J Colorectal Dis 28, 313-323 (2013).
55. Zhao, Y. et al. Targeting insulin resistance in type 2 diabetes via immune modulation of cord blood-derived multipotent stem cells (CB-SCs) in stem cell educator therapy: phase I/II clinical trial. BMC Medicine 11, 1-13 (2013).
56. Shin, K. et al. Hedgehog/Wnt feedback supports regenerative proliferation of epithelial stem cells in bladder. Nature 472, 110-114 (2011).
57. Jin, J. H. et al. Senescence associated MCP-1 secretion is dependent on a decline in BMI1 in human mesenchymal stromal cells. Antioxid. Redox Signal. 24, 471-485 (2016).